CELSR3 and neoplasm: Hits were triaged in biophysical and cellular assays and several potent binders identified and expressed as bispecific mAbs (bs-mAb) designed to simultaneously bind to CELSR3 on a tumor cell and the CD3 receptor present on human T cells.